Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2020

CEL-SCI to develop Covid-19 immunotherapy

Biotechnology company CEL-SCI has begun efforts to develop an immunotherapy for the potential treatment of Covid-19 coronavirus infection.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Biotechnology company CEL-SCI has begun efforts to develop an immunotherapy for the potential treatment of Covid-19 coronavirus infection.

The company will leverage its LEAPS peptide technology, which could enable immunotherapeutic peptides with antiviral, as well as anti-inflammatory effects.

CEL-SCI notes that LEAPS peptides will use conserved regions of coronavirus proteins to induce protective cell-mediated T-cell responses and also decrease viral load.

In addition to acting on the viral infection, these peptides should trigger a protective response.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Previously, the LEAPS peptides were tested against another respiratory virus, called pandemic influenza (H1N1), in studies performed in alliance with the National Institutes for Allergies and Infectious Diseases (NIAID).

Findings in mice models showed protection from morbidity and mortality via activation of T-cell responses instead of an inflammatory response.

CEL-SCI cellular immunology senior vice-president of research Daniel Zimmerman said: “We believe that a LEAPS Covid-19 coronavirus peptide will reduce or arrest the progression of the virus infection and prevent tissue damage from inflammation resulting from lung infection by the virus.

“In short, we believe that we can stimulate the correct immune responses to the virus without producing unwanted inflammatory responses associated with lung tissue damage. That should be particularly important in the older population who is at highest risk of dying from this virus.”

The proposed LEAPS peptides will target antigens in Covid-19’s NP protein and trigger cytolytic T-cell responses, said the company.

CEL-SCI adds that cytolytic T-cell responses target the cellular ‘factories’ infected by the virus within the host and eliminate the source of the infection.

 

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU